Sponsors

A global pharmaceutical company. Our purpose is to push the boundaries of science to deliver life-changing medicines. The best way we can help patients is to be science-led and share this passion with the scientific, healthcare and business communities.

Evinova is a global health tech company empowering life‑science leaders to accelerate clinical development with proven AI‑native and digital solutions..

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and Twitter @Fortrea.

Panthera is the UK’s largest independent Site Management Organisation (SMO), specialising in patient recruitment and the delivery of clinical trials through its network of seven dedicated research clinics across the UK. Working in partnership with leading CROs and pharmaceutical companies, Panthera provides rapid, reliable access to millions of potential participants, enabling the recruitment of thousands of patients at speed.

Dr Ian Smith MBE, one of Panthera’s founders, pioneered the SMO model. Since its launch in 2019, Panthera has redefined clinical trial delivery in the UK. In just a few years, it has become the market leader, supporting ten of the world’s top twelve pharmaceutical companies and seven of the leading CROs.

Panthera is recognised for its ability to deliver high-quality trials quickly and efficiently - providing sponsors with certainty, accelerating study timelines, and streamlining the path to commercialisation.

In August 2025, Panthera secured investment from leading private equity investor LDC to support its continued expansion and enhance its clinical capabilities.

Performance and Achievements:

• Offers the widest range of clinical trial therapy areas of any UK SMO, covering Alzheimer’s, oncology, cardiovascular disease, metabolic studies, respiratory conditions, vaccines, rheumatology/immunology, neurology, and more.

• Consistently the first sites to pre-screen, screen and randomise patients in the UK, EU and sometimes Globally due to exceptional start up timelines.

• Ranked top global recruiter in four studies and top UK recruiter in six more over the past two years (Often contributing 50%+ of the UK participants in therapy areas such as CVD, Vaccines and CNS)

• Achieving Alliance/strategic partnership level with most top tier CRO organisations.

• Has built the largest and most digitally advanced patient database and study access model ever seen in the UK driving active engagements with over 300,000 patient candidates.

Panthera’s success is built on its rapid study start-up capabilities, broad patient access, and the expertise of its experienced Principal Investigators and management team - ensuring high-quality research and a collaborative approach to every partnership.

For more information, visit www.panthera-bio.com

As a leading global clinical research organization (CRO), Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, our therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in our DNA. Our employees have a deep conviction in what we do, and together with our customers, we are shaping the next generation of therapies, one patient at a time. What we do, we do With Heart™.

PPD is delighted to sponsor PharmaTimes International Clinical Researcher of the Year 2023.

PPD is a leading global contract research organisation providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organisations. With locations in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.

Worldwide Clinical Trials (Worldwide) is a leading global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications, from discovery to reality. Our full-service clinical development capabilities include bioanalytical laboratory services and Phase I-IV clinical trials, as well as post-approval and real-world evidence studies – all powered by our talented and accessible team of clinicians, scientists, and researchers who bring their first-hand expertise to each clinical program.

At Worldwide, we understand that each customer and project are unique, so we take a collaborative and personalized approach to identify and meet specific needs and goals. Anchored in our company’s scientific heritage, we are therapeutically focused on cardiovascular, metabolic, neuroscience, oncology, and rare diseases. We apply this deep therapeutic knowledge to develop flexible plans and quickly solve problems in the rapidly evolving clinical development landscape.

Our team of 3,000+ professionals spans 60+ countries, and believes that through collaboration, and a culture that embraces diversity, equity, inclusion, and belonging (DEI&B), everyone plays an important role in making a world of difference for patients and their caregivers. We are united in cause with our customers to improve the lives of patients through new, innovative therapies.

For more information on Worldwide, visit www.Worldwide.com or connect with us on LinkedIn.